<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37071594</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Abl kinase-mediated FUS Tyr526 phosphorylation alters nucleocytoplasmic FUS localization in FTLD-FUS.</ArticleTitle><Pagination><StartPage>4088</StartPage><EndPage>4104</EndPage><MedlinePgn>4088-4104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awad130</ELocationID><Abstract><AbstractText>Nuclear to cytoplasmic mislocalization and aggregation of multiple RNA-binding proteins (RBPs), including FUS, are the main neuropathological features of the majority of cases of amyotrophic lateral sclerosis (ALS) and frontotemporal lobular degeneration (FTLD). In ALS-FUS, these aggregates arise from disease-associated mutations in FUS, whereas in FTLD-FUS, the cytoplasmic inclusions do not contain mutant FUS, suggesting different molecular mechanisms of FUS pathogenesis in FTLD that remain to be investigated. We have previously shown that phosphorylation of the C-terminal Tyr526 of FUS results in increased cytoplasmic retention of FUS due to impaired binding to the nuclear import receptor TNPO1. Inspired by the above notions, in the current study we developed a novel antibody against the C-terminally phosphorylated Tyr526 FUS (FUSp-Y526) that is specifically capable of recognizing phosphorylated cytoplasmic FUS, which is poorly recognized by other commercially available FUS antibodies. Using this FUSp-Y526 antibody, we demonstrated a FUS phosphorylation-specific effect on the cytoplasmic distribution of soluble and insoluble FUSp-Y526 in various cells and confirmed the involvement of the Src kinase family in Tyr526 FUS phosphorylation. In addition, we found that FUSp-Y526 expression pattern correlates with active pSrc/pAbl kinases in specific brain regions of mice, indicating preferential involvement of cAbl in the cytoplasmic mislocalization of FUSp-Y526 in cortical neurons. Finally, the pattern of immunoreactivity of active cAbl kinase and FUSp-Y526 revealed altered cytoplasmic distribution of FUSp-Y526 in cortical neurons of post-mortem frontal cortex tissue from FTLD patients compared with controls. The overlap of FUSp-Y526 and FUS signals was found preferentially in small diffuse inclusions and was absent in mature aggregates, suggesting possible involvement of FUSp-Y526 in the formation of early toxic FUS aggregates in the cytoplasm that are largely undetected by commercially available FUS antibodies. Given the overlapping patterns of cAbl activity and FUSp-Y526 distribution in cortical neurons, and cAbl induced sequestration of FUSp-Y526 into G3BP1 positive granules in stressed cells, we propose that cAbl kinase is actively involved in mediating cytoplasmic mislocalization and promoting toxic aggregation of wild-type FUS in the brains of FTLD patients, as a novel putative underlying mechanism of FTLD-FUS pathophysiology and progression.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Motaln</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Jo&#x17e;ef Stefan Institute, SI-1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x10c;er&#x10d;ek</LastName><ForeName>Ur&#x161;a</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Jo&#x17e;ef Stefan Institute, SI-1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Biomedicine, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamoah</LastName><ForeName>Alfred</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, RWTH Aachen University Medical School, 52074 Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathi</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, RWTH Aachen University Medical School, 52074 Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronica</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Amsterdam UMC location University of Amsterdam, Department of Neuropathology, Amsterdam Neuroscience, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Anand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, RWTH Aachen University Medical School, 52074 Aachen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Eleanor and Lou Gherig ALS Center, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogelj</LastName><ForeName>Boris</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-3898-1943</Identifier><AffiliationInfo><Affiliation>Department of Biotechnology, Jo&#x17e;ef Stefan Institute, SI-1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Chemistry and Chemical Technology, University of Ljubljana, SI-1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.12</RegistryNumber><NameOfSubstance UI="C116070">G3BP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075223">Poly-ADP-Ribose Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067776">RNA Recognition Motif Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D016315">Proto-Oncogene Proteins c-abl</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075223" MajorTopicYN="N">Poly-ADP-Ribose Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067776" MajorTopicYN="N">RNA Recognition Motif Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016315" MajorTopicYN="N">Proto-Oncogene Proteins c-abl</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">c-Abl</Keyword><Keyword MajorTopicYN="N">c-Src</Keyword><Keyword MajorTopicYN="N">cytoplasmic aggregates</Keyword><Keyword MajorTopicYN="N">phosphorylation</Keyword></KeywordList><CoiStatement>The authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>13</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37071594</ArticleId><ArticleId IdType="pmc">PMC10545532</ArticleId><ArticleId IdType="doi">10.1093/brain/awad130</ArticleId><ArticleId IdType="pii">7127731</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kwiatkowski TJJ, Bosco DA, Leclerc AL, et al. . Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, et al. . Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Ghoshal N. FUS: a new actor on the frontotemporal lobar degeneration stage. Neurology. 2010;74:354&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">20124200</ArticleId></ArticleIdList></Reference><Reference><Citation>Prpar Mihevc S, Darovic S, Kovanda A, Bajc &#x10c;esnik A, &#x17d;upunski V, Rogelj B. Nuclear trafficking in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Brain. 2017;140:13&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">27497493</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, et al. . TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, et al. . Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogelj B, Easton LE, Bogu GK, et al. . Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain. Sci Rep. 2012;2:603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3429604</ArticleId><ArticleId IdType="pubmed">22934129</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Hu Q, Rollinson S, et al. . The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol. 2011;122:99&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">21424531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhine K, Makurath MA, Liu J, et al. . ALS/FTLD-Linked mutations in FUS glycine residues cause accelerated gelation and reduced interactions with wild-type FUS. Mol Cell. 2020;80:666&#x2013;681.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688085</ArticleId><ArticleId IdType="pubmed">33159856</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M, Laubenthal J, Hermann A. Fused in sarcoma-amyotrophic lateral sclerosis as a novel member of DNA single strand break diseases with pure neurological phenotypes. Neural Regen Res. 2021;16:110&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818870</ArticleId><ArticleId IdType="pubmed">32788458</ArticleId></ArticleIdList></Reference><Reference><Citation>Troakes C, Hortob&#xe1;gyi T, Vance C, Al-Sarraj S, Rogelj B, Shaw CE. Transportin 1 colocalization with fused in sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions. Neuropathol Appl Neurobiol. 2013;39:553&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">22934812</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, Sun F, Chen J, et al. . Amyloid-Forming segment induces aggregation of FUS-LC domain from phase separation modulated by site-specific phosphorylation. J Mol Biol. 2020;432:467&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">31805282</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoads SN, Monahan ZT, Yee DS, et al. . The prionlike domain of FUS is multiphosphorylated following DNA damage without altering nuclear localization. Mol Biol Cell. 2018;29:1786&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085830</ArticleId><ArticleId IdType="pubmed">29897835</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Erauskin J, Tadokoro T, Baughn MW, et al. . ALS/FTD-linked mutation in FUS suppresses intra-axonal protein synthesis and drives disease without nuclear loss-of-function of FUS. Neuron. 2018;100:816&#x2013;830.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6277851</ArticleId><ArticleId IdType="pubmed">30344044</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysikova EA, Kukharsky MS, Chaprov KD, et al. . Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration. Genes Brain Behav. 2019;18:e12607.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysikova EA, Funikov S, Rezvykh AP, et al. . Low level of expression of C-terminally truncated human FUS causes extensive changes in the spinal cord transcriptome of asymptomatic transgenic mice. Neurochem Res. 2020;45:1168&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">32157564</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova TA, Peters OM, Deykin AV, et al. . Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem. 2013;288:25266&#x2013;25274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757190</ArticleId><ArticleId IdType="pubmed">23867462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, McGoldrick P, Vance C, et al. . Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125:273&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549237</ArticleId><ArticleId IdType="pubmed">22961620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Lim L, Song J. ATP Enhances at low concentrations but dissolves at high concentrations liquid-liquid phase separation (LLPS) of ALS/FTD-causing FUS. Biochem Biophys Res Commun. 2018;504:545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">30205960</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray DT, Kato M, Lin Y, et al. . Structure of FUS protein fibrils and its relevance to self-assembly and phase separation of low-complexity domains. Cell. 2017;171:615&#x2013;627.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650524</ArticleId><ArticleId IdType="pubmed">28942918</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J. Liquidizing FUS via prion-like domain phosphorylation. EMBO J. 2017;36:2925&#x2013;2927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641903</ArticleId><ArticleId IdType="pubmed">28963393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K, Ishigaki S, Iguchi Y, et al. . Characteristic features of FUS inclusions in spinal motor neurons of sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2020;79:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">32142134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tischbein M, Baron DM, Lin Y-C, et al. . The RNA-binding protein FUS/TLS undergoes calcium-mediated nuclear egress during excitotoxic stress and is required for GRIA2 mRNA processing. J Biol Chem. 2019;294:10194&#x2013;10210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6664169</ArticleId><ArticleId IdType="pubmed">31092554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindstr&#xf6;m M, Liu B. Yeast as a model to unravel mechanisms behind FUS toxicity in amyotrophic lateral sclerosis. Front Mol Neurosci. 2018;11:218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6031741</ArticleId><ArticleId IdType="pubmed">30002616</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen I, Shewmaker F. The role of post-translational modifications in the phase transitions of intrinsically disordered proteins. Int J Mol Sci. 2019;20:5501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6861982</ArticleId><ArticleId IdType="pubmed">31694155</ArticleId></ArticleIdList></Reference><Reference><Citation>Darovic S, Prpar Mihevc S, &#x17d;upunski V, et al. . Phosphorylation of C-terminal tyrosine residue 526 in FUS impairs its nuclear import. J Cell Sci. 2015;128:4151&#x2013;4159.</Citation><ArticleIdList><ArticleId IdType="pubmed">26403203</ArticleId></ArticleIdList></Reference><Reference><Citation>Qamar S, Wang G, Randle SJ, et al. . FUS Phase separation is modulated by a molecular chaperone and methylation of arginine cation-&#x3c0; interactions. Cell. 2018;173:720&#x2013;734.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927716</ArticleId><ArticleId IdType="pubmed">29677515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M, Hutten S, Bourgeois B, et al. . Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell. 2018;173:706&#x2013;719.e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Monahan Z, Ryan VH, Janke AM, et al. . Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity. EMBO J. 2017;36:2951&#x2013;2967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641905</ArticleId><ArticleId IdType="pubmed">28790177</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizawa T, Ali R, Jiou J, et al. . Nuclear import receptor inhibits phase separation of FUS through binding to multiple sites. Cell. 2018;173:693&#x2013;705.e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234985</ArticleId><ArticleId IdType="pubmed">29677513</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, et al. . Nuclear-Import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173:677&#x2013;692.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V, Nozal V, Rojas-Prats E, Gil C, Martinez A. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. Br J Pharmacol. 2021;178:1316&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">32737989</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Q, Holler CJ, Taylor G, et al. . FUS Is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. J Neurosci. 2014;34:7802&#x2013;7813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044245</ArticleId><ArticleId IdType="pubmed">24899704</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen I, Rhoads S, Yee D, et al. . The prion-like domain of fused in sarcoma is phosphorylated by multiple kinases affecting liquid- and solid-phase transitions. Mol Biol Cell. 2020;31:2522&#x2013;2536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7851872</ArticleId><ArticleId IdType="pubmed">32877292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ait-Bouziad N, Chiki A, Limorenko G, Xiao S, Eliezer D, Lashuel HA. Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of tau. J Biol Chem. 2020;295:7905&#x2013;7922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7278352</ArticleId><ArticleId IdType="pubmed">32341125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BW, Jeong YE, Wong M, Martin LJ. DNA Damage accumulates and responses are engaged in human ALS brain and spinal motor neurons and DNA repair is activatable in iPSC-derived motor neurons with SOD1 mutations. Acta Neuropathol Commun. 2020;8:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6995159</ArticleId><ArticleId IdType="pubmed">32005289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SL, Tran DN, Kieu Z, et al. . Genetic ablation of hematopoietic cell kinase accelerates Alzheimer&#x2019;s disease-like neuropathology in Tg2576 mice. Mol Neurobiol. 2020;57:2447&#x2013;2460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187907</ArticleId><ArticleId IdType="pubmed">32146679</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez DA, Vargas LM, Chandia-Cristi A, de la Fuente C, Leal N, Alvarez AR. c-Abl deficiency provides synaptic resiliency against A&#x3b2;-oligomers. Front Cell Neurosci. 2019;13:526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902026</ArticleId><ArticleId IdType="pubmed">31849613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko HS, Lee Y, Shin J-H, et al. . Phosphorylation by the c-abl protein tyrosine kinase inhibits parkin&#x2019;s ubiquitination and protective function. Proc Natl Acad Sci U S A. 2010;107:16691&#x2013;16696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944759</ArticleId><ArticleId IdType="pubmed">20823226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong HSJ, Nona M, Guerra SB, VanBerkum MF. The first quarter of the C-terminal domain of abelson regulates the WAVE regulatory complex and enabled in axon guidance. Neural Dev. 2020;15:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196227</ArticleId><ArticleId IdType="pubmed">32359359</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraj V, Theis T, Johal AS, et al. . Application of antibodies to neuronally expressed Nogo-A increases neuronal survival and neurite outgrowth. Int J Mol Sci. 2020;21:5417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7432704</ArticleId><ArticleId IdType="pubmed">32751444</ArticleId></ArticleIdList></Reference><Reference><Citation>Luttrell LM, Ferguson SS, Daaka Y, et al. . Beta-arrestin-dependent formation of beta2 adrenergic receptor-src protein kinase complexes. Science. 1999;283:655&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">9924018</ArticleId></ArticleIdList></Reference><Reference><Citation>Motaln H, &#x10c;er&#x10d;ek U, Recek N, Bajc &#x10c;esnik A, Mozeti&#x10d; M, Rogelj B. Cold atmospheric plasma induces stress granule formation via an eIF2&#x3b1;-dependent pathway. Biomater Sci. 2020;8:5293&#x2013;5305.</Citation><ArticleIdList><ArticleId IdType="pubmed">32930691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo&#x17e;i&#x10d; J, Motaln H, Jane&#x17e; AP, et al. . Interactome screening of C9orf72 dipeptide repeats reveals VCP sequestration and functional impairment by polyGA. Brain. 2022;145:684&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014755</ArticleId><ArticleId IdType="pubmed">34534264</ArticleId></ArticleIdList></Reference><Reference><Citation>Nango H, Kosuge Y, Sato M, et al. . Highly efficient conversion of motor neuron-like NSC-34 cells into functional motor neurons by prostaglandin E(2). Cells. 2020;9:1741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409148</ArticleId><ArticleId IdType="pubmed">32708195</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi P, Guo H, Dreser A, et al. . Pathomechanisms of ALS8: altered autophagy and defective RNA binding protein (RBP) homeostasis due to the VAPB P56S mutation. Cell Death Dis. 2021;12:466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8110809</ArticleId><ArticleId IdType="pubmed">33972508</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamoah A, Tripathi P, Sechi A, et al. . Aggregates of RNA binding proteins and ER chaperones linked to exosomes in granulovacuolar degeneration of the Alzheimer&#x2019;s disease brain. J Alzheimers Dis. 2020;75:139&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">32250292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dephoure N, Gould KL, Gygi SP, Kellogg DR. Mapping and analysis of phosphorylation sites: a quick guide for cell biologists. Mol Biol Cell. 2013;24:535&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3583658</ArticleId><ArticleId IdType="pubmed">23447708</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyster J, Baskaran R, Wang JY. Src homology 2 domain as a specificity determinant in the c-abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc Natl Acad Sci U S A. 1995;92:1555&#x2013;1559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42558</ArticleId><ArticleId IdType="pubmed">7533294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez Lain A, Millecamps S, Dubourg O, et al. . Abnormal TDP-43 and FUS proteins in muscles of sporadic IBM: similarities in a TARDBP-linked ALS patient. J Neurol Neurosurg Psychiatry. 2011;82:1414&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pubmed">20562395</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Watanabe A, et al. . The src/c-abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaaf3962.</Citation><ArticleIdList><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrotti D, Iervolino A, Cesi V, et al. . BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway. Mol Cell Biol. 2000;20:6159&#x2013;6169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86091</ArticleId><ArticleId IdType="pubmed">10913197</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Scotter EL, Nishimura AL, et al. . ALS Mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum Mol Genet. 2013;22:2676&#x2013;2688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674807</ArticleId><ArticleId IdType="pubmed">23474818</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Ding X, Akram N, Xue S, Luo S-Z. Fused in sarcoma: properties, self-assembly and correlation with neurodegenerative diseases. Molecules. 2019;24:1622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6514960</ArticleId><ArticleId IdType="pubmed">31022909</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Rodde R, Edbauer D, et al. . ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. EMBO J. 2010;29:2841&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J, Sendscheid O, El Oussini H, et al. . Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J. 2016;35:1077&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868956</ArticleId><ArticleId IdType="pubmed">26951610</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Valori CF, Ansorge O, et al. . Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathol. 2012;124:705&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">22842875</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Neumann M, Arzberger T, et al. . Monomethylated and unmethylated FUS exhibit increased binding to transportin and distinguish FTLD-FUS from ALS-FUS. Acta Neuropathol. 2016;131:587&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">26895297</ArticleId></ArticleIdList></Reference><Reference><Citation>Gschwendt M, Kielbassa K, Kittstein W, Marks F. Tyrosine phosphorylation and stimulation of protein kinase C delta from porcine spleen by src in vitro. Dependence on the activated state of protein kinase C delta. FEBS Lett. 1994;347:85&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">7516899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kino Y, Washizu C, Kurosawa M, et al. . FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2015;3:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408580</ArticleId><ArticleId IdType="pubmed">25907258</ArticleId></ArticleIdList></Reference><Reference><Citation>Baade I, Hutten S, Sternburg EL, et al. . The RNA-binding protein FUS is chaperoned and imported into the nucleus by a network of import receptors. J Biol Chem. 2021;296:100659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131929</ArticleId><ArticleId IdType="pubmed">33857479</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson MA, Deng Q, Taylor G, et al. . Divergent FUS phosphorylation in primate and mouse cells following double-strand DNA damage. Neurobiol Dis. 2020;146:105085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8064403</ArticleId><ArticleId IdType="pubmed">32950644</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>